Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 19, 2008
[Marked effect of combination chemotherapy with tegafur-gimeracil-oteracil potassium and gemcitabine on a suspected case of pancreas cancer or gallbladder cancer metastasis to bone: further diagnosis of disseminated carcinomatosa of bone marrow recurrence after the 23 years of gastric cancer operation by autopsy findings]Akihiro Sakai, Yoshihisa Tsuji, Osamu Kikuchi, et al.
Scientific Reports|January 24, 2020
Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathwayKazuhiro Murai, Hayato Hikita, Yugo Kai, et al.
Plos One|December 21, 2022
Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosisKumiko Shirai, Hayato Hikita, Ryotaro Sakamori, et al.
Cancers|January 21, 2023
Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting AntiviralTakayuki Matsumae, Takahiro Kodama, Yuki Tahata, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 12, 2022
Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosisYuki Tahata, Ryotaro Sakamori, Kazuki Maesaka, et al.
Alimentary Pharmacology & Therapeutics|November 23, 2021
Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus eliminationYuta Myojin, Hayato Hikita, Yuki Tahata, et al.
Plos One|February 7, 2023
Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinomaKazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, et al.
Plos One|January 2, 2024
Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational studyMachiko Kai, Hayato Hikita, Maesaka Kazuki, et al.
Journal of Gastroenterology and Hepatology|September 9, 2025
Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular CarcinomaKazuki Maesaka, Hayato Hikita, Machiko Kai, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 16, 2025
The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long-Term Administration of Nucleos(t)ide AnalogsKazuhiro Murai, Hayato Hikita, Ryoko Yamada, et al.
Pageof 7